• CalendarApril 2, 2019 – 2019 Business Methods Partnership Meeting (U.S. Patent and Trademark Office) – 10:00 am to 3:00 pm (ET) on 

    April 4, 2019 – "Standing to Appeal from the PTAB" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    April 4, 2019 – "Can My Blockchain Do That? A Discussion of Blockchain Beyond Cryptocurrency" (Intellectual Property Law Association of Chicago Corporate Committee and Advertising and Digital Committee) – 5:15 to 6:15 pm (CT), Chicago, IL

    April 29-30, 2019 – Paragraph IV Disputes master symposium (American Conference Institute) – New York, NY

    April 23, 2019 – "Recent Developments in Biopharma Patent Law" (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:30 pm, San Diego, CA (Hyatt Regency La Jolla at Aventine)

    April 24, 2019 – "Recent Developments in Biopharma Patent Law" (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:30 pm, Burlingame, CA (Hyatt Regency San Francisco Airport)

    May 16-17, 2019 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY

  • MBHB Logo 2McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs will be hosting two onsite CLE programs on "Recent Developments in Biopharma Patent Law" from 9:30 am to 1:30 pm (PT) on April 23, 2019 in San Diego, CA (Hyatt Regency La Jolla at Aventine) and on April 24, 2019 in Burlingame, CA (Hyatt Regency San Francisco Airport).  MBHB attorneys and Patent Docs authors Kevin Noonan and Donald Zuhn, and MBHB attorneys Josh Rich, Lisa Hillman, Sarah Fendrick, John Conour, Nate Chongsiriwatana, and Nicole Grimm will provide presentations on the following topics:

    • Updates on Subject Matter Eligibility Analysis
    • Patenting Repurposed Drugs
    • Antibody Patenting after Amgen v. Sanofi
    The State of Biotech Patenting: Challenges
    • Maximizing Patent Term for Products Subject to Regulatory Review
    • Impact of Secondary Patents on Market Exclusivity
    • Considerations for Biotech Cannabis Patents
    • Strategies for Post-Grant Proceedings for Generics and Biosimilars

    There is no registration fee for the program.  However, because space is limited, those interested in attending the program must register by contacting Susan Hall at hall@mbhb.com.  When registering, please note at which location you plan to attend:  San Diego or Burlingame.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Standing to Appeal from the PTAB" on April 4, 2019 from 2:00 to 3:00 pm (ET).  Neal Dahiya of Bristol-Myers Squibb Company; Michael Flibbert of Finnegan, Henderson, Farabow, Garrett & Dunner, LLP; Michael Rosato of Wilson Sonsini Goodrich & Rosati will also address strategies for obtaining, and opposing, appellate standing.  The panel will discuss:

    • The argument that injury from IPR estoppel in future district court litigation, after a losing challenge, is enough to create standing;
    • The theory that standing is created after an unsuccessful challenge because a patent impedes research;
    • Other strategies for making the case for and against standing;
    • The recently argued U.S. Supreme Court case of Return Mail;
    • The Court's request for the Solicitor General's views regarding the pending petition for writ of certiorari in RPX Corp. v. ChanBond LLC; and
    • Procedural details for appeals related to standing.

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • ACIAmerican Conference Institute (ACI) will be holding its 17th Advanced Summit on Life Sciences Patents conference on May 16-17, 2019 in New York, NY.

    The conference will offer presentations on the following topics:

    • Patenting strategies for U.S. and Europe
    • What's new at the PTAB?
    • The "new" § 101 landscape in the PTO and District Courts
    • Obviousness-type double patenting
    • Printed publication standards at the PTAB
    • FTO and avoiding future infringement
    • Prolonging patent lifecycles in US, EP, and JP
    • Revisiting the Doctrine of Equivalence
    • Antibody patent review: global perspectives
    • Applying the written description requirement to antibody claims
    • Europe post-Brexit and the Unitary Patent Regime
    • The intersection between high-tech, data mining, discovery and patent protection
    • Ethics in life sciences patent prosecution

    In addition, two pre-conference workshops will be offered on May 15, 2019.  The first, entitled "Patents Around the World Working Group" will be offered from 9:00 am to 12:30 pm, and the second, entitled "Antibody Claims Drafting Master Class" will be offered from 1:30 to 5:00 pm.

    The agenda for the Paragraph IV Disputes conference can be found here.  More information regarding the workshops can be found here and here.  A complete brochure for this conference, including an agenda, detailed descriptions of conference sessions, list of speakers, and registration form can be obtained here.

    The registration fee for the conference alone is $2,095 (by April 5th) or $2,295 (by May 14th). The workshops carry an additional fee of $600 apiece.  Patent Docs readers are entitled to a 10% discount off of registration using discount code P10-999-PTD19.  Those interested in registering for the conference can do so here, by e-mailing CustomerService@AmericanConference.com, or by calling 1-888-224-2480.

    Patent Docs is a media partner of ACI's 17th Advanced Summit on Life Sciences Patents Conference.

  • IPLACThe Intellectual Property Law Association of Chicago (IPLAC) Corporate Committee and Advertising and Digital Committee will be presenting a program entitled "Can My Blockchain Do That? A Discussion of Blockchain Beyond Cryptocurrency" on April 4, 2019 from 5:15 to 6:15 pm (CT) at DePaul College of Law in Chicago, IL.  Bo An, Risk Management, Federal Reserve Bank of Chicago will moderate a panel consisting of Sarah Duda, Assistant General Counsel, Cboe Global Markets; Ted Tian, Master Agreements Negotiator, BP America, Inc.; Mark Fields, Partner, Alsop Louie Partners; and Matthew Kelly, Managing Director and Chief Intellectual Property Counsel, CME Group.  The program will provide an overview of blockchain technology, the value of developing and patenting blockchain and the impact of blockchain technology as it is currently being used, including the VAKT Consortium.

    There is no registration fee IPLAC members.  Those interested in registering for event can do so here.

  • USPTO SealThe U.S. Patent and Trademark Office will be holding the 2019 Business Methods Partnership Meeting from 10:00 am to 3:00 pm (ET) on April 2, 2019.  The meeting is an opportunity to bring stakeholders together to share ideas, experiences, and insights and to provide a forum for an informal discussion of many topics specific to the business methods area.

    The meeting will be held in the USPTO's Alexandria, VA headquarters and its Texas Regional Office in Dallas.  WebEx access will also be available to allow individuals to participate remotely.

    Those wishing to attend the meeting can register should e-mail businessmethods@uspto.gov or contact Mathew Gart at 571-272-3955, Ilana Spar at 571-270-7537, Peter Choi at 469-295-9171, or Victoria Shumate at 313-446-4858.  Additional information regarding the customer partnership meeting can be found here.

  • Claims for Monitoring and Analyzing Suspicious Network Activity Found Patent Eligible

    By James Korenchan

    In a precedential decision issued last week, the Federal Circuit affirmed the U.S. District Court for the District of Delaware's ruling that Plaintiff SRI International, Inc.'s ("SRI") claims related to network security are patent eligible.

    Years ago, SRI sued Defendant Cisco Systems, Inc. ("Cisco") for infringement of U.S. Patent Nos. 6,711,615 (the '615 patent) and 6,484,203 (the '203 patent), after which Cisco unsuccessfully moved for summary judgement on various issues, including patent-ineligibility of the claims and whether one of SRI's papers on its own network security tool anticipates the claims.  Cisco then appealed the final judgement of the District Court with respect to these two issues, as well as issues relating to the District Court's construction of the claim term "network traffic data," denial of JMOL of no willful infringement, and grant of enhanced damages, attorneys' fees, and ongoing royalties.  This post addresses only the issue of patent eligibility, including a notable dissenting opinion by Judge Alan David Lourie.

    The Majority Opinion

    The majority opinion focuses on claim 1 of the '615 patent, which the Court adopted as representative.  The Court stated that claim 1 of the '615 patent and claim 1 of the '203 patent are "substantially similar" with differences that are not material to any issue on appeal.  The claimed invention is generally related to network surveillance for the purposes of security in an enterprise network.  For example, this can be accomplished by looking at packets that monitor data transfers, errors, or network connections, building statistical profiles based on packet measurements, using the profiles to determine whether there is suspicious activity, and notifying various hierarchically-related network monitors of the suspicious activity.

    1.  A computer-automated method of hierarchical event monitoring and analysis within an enterprise network comprising:
        deploying a plurality of network monitors in the enterprise network; detecting, by the network monitors, suspicious network activity based on analysis of network traffic data selected from one or more of the following categories: {network packet data transfer commands, network packet data transfer errors, network packet data volume, network connection requests, network connection denials, error codes included in a network packet, network connection acknowledgements, and network packets indicative of well-known network-service protocols};
        generating, by the monitors, reports of said suspicious activity; and
        automatically receiving and integrating the reports of suspicious activity, by one or more hierarchical monitors.

    In Alice Corp. v. CLS Bank Int'l, the Supreme Court set forth a two-step framework for determining whether claims are directed to patent-eligible subject matter under § 101.  First, it must be decided whether a claim is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then it must be decided whether any element or combination of elements in the claim is sufficient to transform the nature of the claim into a patent-eligible application.  To transform an abstract idea into a patent-eligible application, the claims must do more than simply state an abstract idea and broadly recite applying the abstract idea.

    In addressing the issue of patent eligibility, Cisco asserted that the claims are simply directed to a known business process of analyzing data from multiple sources to detect suspicious activity.  But the District Court held that the claims are "more complex" than that.  The District Court concluded that the claims recite a specific process rooted in computer technology — namely, using network monitors that each monitor and analyze specific types of network data, and integrating reports produced by those monitors — in order to solve a specific problem arising in the realm of network computing — namely, detecting hackers or other unwanted activity in a network.  The Federal Circuit agreed.  Citing Enfish, the Court affirmed that the "'focus of the claims is on the specific asserted improvement in computer capabilities'—that is, providing a network defense system that monitors network traffic in real-time to automatically detect large-scale attacks."  For at least this reason, the Court agreed with the District Court's conclusion that the claims are not directed to an abstract idea and are thus patent eligible.

    The Court also pointed to the specification in support of their conclusion.  For example, the specification explains that, in conventional networks, "seemingly localized triggering events can have globally disastrous effects on widely distributed systems," and purports to solve those issues by providing "a framework for the recognition of more global threats to interdomain connectivity, including coordinated attempts to infiltrate or destroy connectivity across an entire network enterprise."

    Cisco provided three main arguments for why the claims are an abstract idea, but the Court refuted each of them.  First, Cisco argued that the claims are analogous to those in Electric Power Group in that they are allegedly directed to generic steps for collecting and analyzing data.  But the Court distinguished these claims from those in Electric Power Group, instead analogizing them to those in DDR Holdings.  In particular, the Court noted that, while the Electric Power Group claims "were drawn to using computers as tools to solve a power grid problem," the claims here, like those in DDR Holdings, "prevent the normal, expected operation of a conventional computer network" — namely, by detecting and reporting on suspicious network activity, as well as by receiving and integrating the reports using one or more hierarchical network monitors.

    Cisco also argued that the claims do not improve computer functionality, per Enfish.  The Court noted how, in Alice, the Supreme Court advised that, even if a claim directed to an abstract idea uses a computer as a tool, the claim still does not pass step one muster.  Using the Supreme Court's notion as a counter to Cisco's argument, the Court stated that the claims are not automating a conventional idea on a computer, but rather recite a specific process that improves the functioning of computer networks in the realm of network security.

    Lastly, Cisco cited a variety of Federal Circuit decisions, such as Intellectual Ventures I LLC v. Symantec Corp. and CyberSource Corp. v. Retail Decisions, Inc., in asserting that the claims are so general that they involve steps that could be performed in one's mind.  But the Court disagreed yet again, noting:

    This is not the type of human activity that § 101 is meant to exclude.  Indeed, we tend to agree with SRI that the human mind is not equipped to detect suspicious activity by using network monitors and analyzing network packets as recited by the claims.

    As such, the Court concluded that the claims are not directed to an abstract idea and are thus patent eligible.  It did not conduct an analysis under step two of the Alice framework.

    Judge Lourie's Dissent

    Judge Lourie wrote a dissent that relied entirely on Electric Power Group.  Practitioners on the tech side of the fence are all too familiar with what might be perceived as an over-reliance on Electric Power Group for § 101 and might view Judge Lourie's dissent with the same skepticism as they've viewed many patent-eligibility issues.

    He first noted that the method recited in Electric Power Group recited "[a] method of detecting events on an interconnected electric power grid in real time over a wide area and automatically analyzing the events on the interconnected electric power grid," with the method comprising eight steps, including "receiving data," "detecting and analyzing events in real time," "displaying the event analysis results and diagnoses of events," "accumulating and updating measurements," and "deriving a composite indicator of reliability."  He emphasized that, despite having eight steps, the Court held that the Electric Power Group claim was an abstract idea without significantly more.  The claim involved selecting information for collection, analysis, and display, was only broadly rooted in computer technology, and, although limited to the context of power-grid monitoring, was still deemed to be patent ineligible.

    Judge Lourie stated that these claims are "hardly distinguishable' from those in Electric Power Group, do not provide enough specifics as to how its steps are performed, show no improvement to computer technology, and are thus directed to the abstract idea of monitoring network security.  In particular, he opined that:

    The claims here recite nothing more than deploying network monitors, detecting suspicious network activity, and generating and handling reports.  The detecting of the suspicious activity is based on "analysis" of traffic data, but the claims add nothing concerning specific means for doing so.  The claims only recite the moving of information.  The computer is used as a tool, and no improvement in computer technology is shown or claimed.  There is no specific technique described for improving computer network security.

    Proceeding to step two, Judge Lourie asserted that, although the claims recite different types of information and information sources, the selection of information does not provide any inventive concept, and the specification indicates that the claims only rely on generic, "customary" computer components.

    Judge Lourie was also not a fan of the majority's partial reliance on the '615 patent's specification:

    [T]he majority opinion quotes from and paraphrases language from the specification that only recites results, not means for accomplishing them.  The claims as written, however, do not recite a specific way of enabling a computer to monitor network activity.  As we noted in Electric Power Group, result-focused, functional claims that effectively cover any solution to an identified problem, like those at issue here, frequently run afoul of Alice.  (citation omitted)

    For these reasons, Judge Lourie strongly opposed the majority's ruling and would have found the claims to be patent ineligible.

    SRI International, Inc. v. Cisco Systems, Inc. (Fed. Cir. 2019)
    Panel:  Circuit Judges Lourie, O'Malley, and Stoll
    Opinion by Circuit Judge Stoll; dissenting opinion by Circuit Judge Lourie

  • By Kevin E. Noonan

    Washington - Capitol #6On March 8th, a canonical "bipartisan of Senators" (a phrase used to signal bills that must be in the public interest because these Senators put aside business as usual to reach across the aisle) introduced S.659, entitled "The Biologic Patent Transparency Act."  These Senators (Collins, R-ME; Kaine, D-VA; Portman, R-OH; Shaheen, D-NH; Braun, R-IN; and Stabenow, D-MI) are purportedly motivated by a desire to reduce prescription drug prices (according to their websites) and have focused on differences between the Biologics Price Competition and Innovation Act (BPCIA) and the Hatch Waxman Act that, in their view, reduces "transparency" to the public's detriment.  But a close look at the provisions of the bill suggest that it solves a problem that doesn't exist and instead focuses on cosmetic changes that have little chance to resolve the issues that have arisen in the implementation of the BPCIA.

    The bill provides for improvements to the so-called "Purple Book," established by the U.S. Food and Drug Administration but insufficiently utilized because listing is not tied to any penalty or disadvantage for failure to list.  The provisions of the bill (Section 2) mandate that Biologics License Applications granted under Section 351(a) of the Public Health Service Act (codified at 42 U.S.C. § 262) or abbreviated Biologics License Applications granted under Section 351(k) of the PHSA must submit to the Secretary of Health and Human Services:

    [A]ny patent for which the holder of a biological product license approved under subsection (a) or (k), or a biological product application approved under section 505 of the Federal Food, Drug, and Cosmetic Act and deemed to be a license for a biological product under this section on March 23, 2020, believes a claim of patent infringement could reasonably be asserted by the holder, or by a patent owner that has granted an exclusive license to the holder with respect to the biological product that is the subject of such license, if a person not licensed by the holder engaged in the making, using, offering to sell, selling, or importing into the United States of the biological product that is the subject of such license.

    In addition, the bill would amend 35 U.S.C. § 271 to include a penalty for non-compliance with this disclosure requirement:

    (7) The owner of a patent that should have been included in the list described in section 351(o)(1) of the Public Health Service Act (42 U.S.C. 262(o)(1)), including any updates require under subparagraph (C) of that section, but was not timely included in such list, may not bring an action under this section for infringement of the patent.

    The Senators, in introducing this bill, seem to believe that implementation of the BPCIA has been inhibited by non-disclosure by reference product sponsors (RPS) of patents that can be asserted against biosimilar applicants to their detriment.

    This sentiment ignores some important facts.  First, the BPCIA already includes a provision, codified at 35 U.S.C. § 271(e)(6)(C), that seriously disincentives a reference product sponsor from failing to notify a biosimilar applicant of relevant patents:

    The owner of a patent that should have been included in the list described in [paragraph 3(A), the patent disclosure of the "patent dance"], but was not timely included in such list, may not bring an action under this section for infringement of the patent with respect to the biological product [emphasis added].

    Second, if any party has been disadvantaged under the BPCIA, it has been the reference product sponsor, as the result of judicial imprimatur of a strategy first employed by Sandoz to not disclose its aBLA or relevant manufacturing information to the RPS.  Enactment of S.659 will not address these issues, which include judicial interpretation of a Congressional mandate ("A biosimilar applicant shall [disclose its aBLA and relevant manufacturing information]"; emphasis added) to be optional.

    Another justification for these changes in the law involves the potential difficulty in a potential biosimilar applicant identifying before the fact (i.e., before a RPS competitor committed to pursuing a biosimilar) multiple patents that might be asserted against the biosimilar applicant.  But these concerns fly in the face of available outlets (for example, www.drugpatentwatch.com) that has this information readily available.

    On the other hand S.659 contains provisions that could increase transparency in useful ways, by establishing "a single, easily searchable, list that includes:

    (i) the official and proprietary name of each biological product licensed under subsection (a) or (k), and of each biological product application approved under section 505 of the Federal Food, Drug, and Cosmetic Act and deemed to be a license for the biological product under this section on March 23, 2020;

    (ii) with respect to each biological product described in clause (i), each patent submitted in accordance with paragraph (1);

    (iii) the date of licensure and application number for each such biological product;

    (iv) the marketing status, dosage form, route of administration, strength, and, if applicable, reference product, for each such biological product;

    (v) the licensure status for each such biological product, including whether the license at the time of listing is approved, withdrawn, or revoked;

    (vi) any period of any exclusivity under subsection (k)(7)(A) or subsection (k)(7)(B) of this section or section 527 of the Federal Food, Drug, and Cosmetic Act, and any extension of such period in accordance with subsection (m) of this section with respect to each such biological product, and the date on which such exclusivity expires;

    (vii) information regarding any determination related to biosimilarity or interchangeability for each such biological product; and

    (viii) information regarding approved indications for each such biological product, in such manner as the Secretary determines appropriate.

    Political posturing is in vogue and particularly posturing regarding prescription drug prices.  'Twould be pretty if 'twere so that patents are the problem; bills like this one promote that narrative but at the cost of addressing systemic issues with drug pricing that will be unaffected by any changes or diminution of patent protection that protects biologic drug innovation.

  • By Donald Zuhn

    District Court for the Central District of CaliforniaEarlier this month, in Chen v. Jung, District Judge Manuel L. Real of the U.S. District Court for the Central District of California issued an order denying a motion for summary judgment filed by Defendants, finding that genuine issues of material fact existed with respect to Plaintiff's contribution to the conception of the claimed inventions of U.S. Patent Nos. 8,445,507, 8,802,689, and 9,388,159.  Plaintiff Degui Chen, Ph.D., had filed suit against Michael Jung, Ph.D., and Charles L. Sawyers, M.D., seeking correction of inventorship of the '507, '689, and '159 patents, which are directed to pharmaceutical compositions comprising the chemical compounds, A51 and A52 ("the A-series compounds"), and methods of administering those compounds.

    In his complaint, Dr. Chen asserted that he had been a significant contributor to the conception of the A-series compounds.  Judge Real's order notes that the A-series compounds, which are used in the treatment of prostate cancer, were developed in the summer of 2004 in two labs at the University of California, Los Angeles, the labs being led by Drs. Jung and Sawyers.  Dr. Chen worked in Dr. Sawyers' lab until September of 2005.  Drs. Jung and Sawyers, along with three other individuals including Dr. Samedy Ouk, are named as inventors on the '507, '689, and '159 patents, which were licensed by The Regents of the University of California to Aargon Pharmaceuticals, Inc. (subsequently acquired by Johnson & Johnson), with the A52 compound ultimately being developed as the drug Erleada.

    Dr. Chen asserted in his complaint that he was involved in a related project (the RD-series) to develop and test compounds for the treatment of prostate cancer.  Dr. Chen contended that he and Dr. Ouk met for lunch in October 2004 to discuss which RD-series compound could be used as a starting point for the development of a new compound, which became A51, and that they jointly came to the conclusion that the compound RD37 could be used.  Dr. Chen also contended that Dr. Ouk e-mailed him on October 13, 2004, to obtain a critical ingredient for the synthesis of A51 and that Ouk successfully synthesized A51 on January 23, 2005.  Dr. Chen further contended that he performed a series of complex bioassays, which he had developed himself, to test the biological activity and utility of A51, and established that A51 had therapeutic biological activity and thus could be developed into a drug for prostate cancer.

    In denying the motion for summary judgment filed by Drs. Jung and Sawyers, Judge Real determined that genuine issues of material fact existed which prevented the entry of summary judgment.  In particular, those issues involved (1) whether the RD-series and A-series were distinct projects, (2) whether Dr. Chen conceived of the idea for A51 in collaboration with Dr. Ouk at the October 2004 lunch meeting, and (3) whether the bioassays Dr. Chen allegedly developed and utilized to test the biologic activity and utility of A51 were a sufficient contribution to conception to qualify Dr. Chen as an inventor on the A-series patents.

    With respect to the first issue, Judge Real found that Dr. Chen "has put forth evidence that he and Dr. Ouk identified RD37 as the starting point for A51 and that his work on another RD-series compound, RD162, was essential to the synthesis of A52," and that the allegations in Dr. Chen's complaint were "sufficient to put Defendants on notice of Plaintiff's theory that the RD-series and A-series are a single project and that his work on the RD-series is a factor supporting his claim for inventorship on the A-series patents."  Drs. Jung and Sawyer also argued that even if Dr. Chen's work on the RD-series provided a foundation for the A-series, that alone was insufficient to confer inventorship because Dr. Chen did not conceive of the addition of a nitrogen molecule to the left-hand ring, a defining characteristic of the A-series compounds.  However, Dr. Chen countered that he did in fact conceive of that idea with Dr. Ouk at the 2004 lunch meeting, and the Court noted that his claim was "supported by multiple documents," including the October 13, 2004 e-mail from Dr. Ouk to Dr. Chen and a November 2013 letter to UCLA from counsel purportedly representing both Dr. Chen and Dr. Ouk that states that "Dr. Ouk and Dr. Chen have both confirmed that they two together conceived the structure of A51 in early October of 2004 on the lunch table at the bombshelter at UCLA."

    With respect to the third issue, Dr. Chen contended that he was responsible for developing three bioassays that were used to test A51, that the development of these bioassays took six months, and that the bioassays were novel tests.  Judge Real noted that Drs. Jung and Sawyers "have not provided evidence sufficient to rebut Plaintiff's claims that the assays were non-public and non-routine, or that Plaintiff's alleged development and utilization of the bioassays were so essential to the A-series project as to confer inventorship."  Finding that "Defendants have not met their burden of negating an essential element of Plaintiff's claim or showing that Plaintiff lacks sufficient evidence of an essential element to carry his ultimate burden of persuasion at trial," the District Court denied the motion for summary judgement filed by Drs. Jung and Sawyer.

    Chen v. Jung (C.D. Cal. 2019)
    Order Denying Defendants' Motion for Summary Judgment by District Judge Real

  • Software Claims Survive Section 101 Challenge and Are Found to Be Directed to Patent-Eligible Subject Matter

    By Joseph Herndon

    USPTO SealIn the U.S. Patent and Trademark Office, the Patent Trial and Appeal Board (PTAB) recently designated its decision in Ex Parte Smith as an informative decision for its application of the revised guidance on the application of 35 U.S.C. § 101.  (Ex parte Eileen C. Smith, Anthony Montesano, Edward T. Tilly, Mark A. Esposito, Stuart J. Kipnes, and Anthony J. Carone, Appeal 2018-000064, Technology Center 3600).

    Below, we analyze the decision, which is favorable for applicants, to illustrate that even when claims are found to be directed to a judicial exception (e.g., abstract idea), they will survive section 101 challenges if additional elements in the claim integrate the judicial exception into a practical application.

    The decision reviewed a rejection of claims under 35 U.S.C. § 101 as being directed to patent-ineligible subject matter.  The claims are directed to a hybrid trading system for concurrently trading securities or derivatives through both electronic and open-outcry trading mechanisms.  Claim 1, reproduced below, is illustrative of the claimed subject matter:

    1.  A method of trading derivatives in a hybrid exchange system comprising:
        collecting orders, via a communication network and order routing system, for derivatives and placing them in an electronic book database;
        identifying at an electronic trade engine a new quote from a first in-crowd market participant, wherein one of a bid or an offer price in the new quote matches a respective price in an order in the electronic book database from a public customer;
        removing at least a portion of the order in the electronic book database, delaying automatic execution of the new quote and the order, and starting a timer;
        reporting, via the communication network and an electronic reporting system, a market quote indicative of execution of the at least a portion of the order while delaying automatic execution;
        receiving at the electronic trade engine a second quote from a second in-crowd market participant after receiving the new quote from the first in-crowd market participant and before an expiration of the timer, wherein the second quote matches the respective price of the public customer order in the electronic book database; and
        allocating the order between the first and second in-crowd market participants at the electronic trade engine, wherein the order is not executed until expiration of the timer.

    Standard for Patent Eligibility

    The PTAB first noted the two-step test set forth by the Supreme Court in Alice, which includes first determining whether the claims at issue are directed to a patent-ineligible concept, and if so, secondly considering the elements of each claim both individually and as an ordered combination to determine whether the additional elements transform the nature of the claim into a patent-eligible application.

    The USPTO recently published revised guidance on the application of § 101.  (USPTO's January 7, 2019 Memorandum, 2019 Revised Patent Subject Matter Eligibility Guidance).  Under that guidance, the USPTO indicated to first look to whether the claim recites:

    (1) any judicial exceptions, including certain groupings of abstract ideas (i.e., mathematical concepts, certain methods of organizing human interactions such as a fundamental economic practice, or mental processes); and
    (2) additional elements that integrate the judicial exception into a practical application. Only if a claim (1) recites a judicial exception and (2) does not integrate that exception into a practical application, do we then look to whether the claim:
    (3) adds a specific limitation beyond the judicial exception that is not "well-understood, routine, conventional" in the field; or
    (4) simply appends well-understood, routine, conventional activities previously known to the industry, specified at a high level of generality, to the judicial exception.

    Examiner's Findings and Conclusion

    In the first step of the Alice inquiry, the Examiner determined that the claims were directed to the abstract idea of comparing new and stored information and using rules to identify options because the claims recite steps such as collecting, identifying, and reporting.  The Examiner further determined the claims are directed to an abstract idea of trading derivatives in a hybrid exchange system which is a concept within the realm of "fundamental economic practices".

    At Alice step 2, the Examiner determined that the claims do not recite elements sufficient to amount to significantly more than the abstract idea because the computer as recited is a generic computer component that performs functions which are generic computer functions.

    Board's Review

    Applying the guidance set forth in the new USPTO Memorandum, the PTAB reversed the decision of the Examiner.

    Like the Examiner, the PTAB first found that the limitations of claim 1, under their broadest reasonable interpretation, recite the fundamental economic practice of derivative trading because the limitations all recite the operations that would ordinarily take place in a derivatives trading environment.  Thus, like the concept of intermediated settlement in Alice, and the concept of hedging in Bilski, the concept of trading derivatives recited in the claims was found to be a fundamental economic practice long prevalent in our system of commerce.  Thus, the claims were found to recite a judicial exception of a fundamental economic practice.

    Having determined that the claims recite a judicial exception and satisfied step 1 of the USPTO memo, the PTAB turned to determining whether there are "additional elements that integrate the judicial exception into a practical application."  Claim 1 recites various computer-related limitations, but at a high level without any meaningful detail about their structure or configuration.  As such, the PTAB did not find the computer-related limitations themselves to be sufficient to integrate the judicial exception into a practical application.

    However, unlike the Examiner, the PTAB found that claim 1 also recites additional limitations which focus on addressing problems arising in the context of a hybrid derivatives trading system in which trades are made both electronically and on a trading floor (i.e., "in the pits").  These limitations include:

    • "delaying automatic execution of the new quote and the order, and starting a timer,"
    • while "delaying automatic execution" of the order, and "before expiration of the timer," receiving a second matching quote "wherein the second quote matches the respective price of the public customer order," and
    • "allocating the order between the first and second in-crowd market participants at the electronic trade engine, wherein the order is not executed until expiration of the timer."

    The PTAB found these additional limitations did, in fact, integrate the recited judicial exception of derivative trading into a practical application.  In particular, these additional elements limit the conventional practice of automatically executing matching market orders by reciting a specific timing mechanism in which the execution of a matching order is delayed for a specific period of time.  The PTAB found that the Specification provided further context to conclude that the use of the claimed timing mechanisms and the associated temporary restraints on execution of trades provided a specific technological improvement over prior derivatives trading systems.

    Because the PTAB determined that the claim is not directed to the recited judicial exception, the claim satisfied section 101 at step 1 of Alice.

    Dissent

    The Dissent disagreed with the conclusion that the additional elements recited in the claims actually integrate the judicial exception of derivative trading into a practical application.

    Namely, the Dissent disagreed with the majority that the use of the claimed timing mechanisms and the associated temporary restraints on execution of trades provides a specific improvement over prior derivatives trading systems.  Instead, the Dissent maintained that the delay of matching market orders, whether 10 minutes, 10 seconds, or even 1 millisecond, is a necessary requirement for both the conventional trading practice or Appellants' derivative trading practice of automatically executing matching market orders, whether on a trading floor (i.e., "in the pits") or electronically.  It was suggested that such timing features themselves are not technical in nature and do not provide any "technical solution to a technical problem".

    The Majority noted, however, that the claimed timing mechanisms are not so trivial.  In fact, the use of the recited "timer" does not occur with each and every trade.  Rather, it is implemented in specific circumstances in a specific trading environment, namely when a matching market order is received from an in-crowd market participant in a hybrid trading system.  Thus, Appellants' claims were found to overcome a problem specifically arising in the realm of computer networks.

    Panel: Administrative Patent Judges Bui, Barry, and Bennett
    Decision on Appeal by Administrative Patent Judge Bennett; dissent by Administrative Patent Judge Bui